Testosterone Levels and Sexual Quality of Life After Stereotactic Body Radiation Therapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials

被引:8
|
作者
Yuan, Ye [1 ]
Aghdam, Nima [2 ]
King, Christopher R. [1 ]
Fuller, Donald B. [3 ]
Weng, Julius [4 ]
Chu, Fang-I. [1 ]
Mardirossian, George [3 ]
Patel, Ankur [1 ]
Nickols, Nicholas G. [1 ,5 ]
Kupelian, Patrick A. [1 ]
Steinberg, Michael L. [1 ]
Collins, Sean P. [2 ]
Kishan, Amar U. [1 ]
机构
[1] Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles, CA 90024 USA
[2] Georgetown Univ, Dept Radiat Oncol, Washington, DC USA
[3] Genesis Cyberknife, San Diego, CA USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[5] VA Greater Los Angeles, Radiat Therapy Serv, Los Angeles, CA USA
关键词
PROTON RADIOTHERAPY;
D O I
10.1016/j.ijrobp.2019.05.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The impact of higher scatter doses per fraction on testicular function and quality of life after prostate stereotactic body radiation therapy (SBRT) is poorly studied. Methods and Materials: Six hundred thirty-six patients treated with SBRT for low- to intermediate-risk prostate cancer from 2009 to 2014 were included. Changes in testosterone and in sexual and hormonal domain scores on the Expanded Prostate Cancer Index Composite-26 (EPIC) questionnaire over a 24-month period were evaluated via a 1-sided t test. EPIC score changes were evaluated in comparison with a distribution-based minimal clinically important difference threshold, wherein changes of greater than one half or greater than one third of the standard deviation in each domain were considered as medium-sized or small-sized effects, respectively. Results: Median and mean percent changes in testosterone at the 3- to 6-month, 7- to 12-month, 13- to 18-month, and 19- to 24-month time periods were -13.41% and -4.49% (P = .02); -12.23% and -2.77% (P = .13); -11.20% and -0.29% (P = .47); -5.00% and + 1.20% (P = .65). When analyzed after dividing the cohort into 3 groups based on baseline testosterone values using tertiles, testosterone tended to increase in patients in the first group and decrease in patients in the third group. Overall, the decline in EPIC hormonal domain scores never exceeded the threshold for a small-sized effect, though the decline in EPIC sexual domain scores did pass this threshold at the 19- to 24-month time period (mean 10.90 point decline). This decline was not present when groups were examined individually. Conclusions: In this large cohort of prospectively followed patients, there was a transient decline in testosterone shortly after SBRT that normalized by 24 months posttreatment. There was no significant change in EPIC hormonal domain scores. A significant decline in EPIC sexual domain scores, consistent with a small-sized clinically detectable difference, manifested between 19 and 24 months of follow-up. These results are consistent with testosterone decline patterns and sexual function changes seen after other forms of photon-based radiation therapy. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:149 / 154
页数:6
相关论文
共 50 条
  • [1] Testosterone Levels and Sexual Quality of Life Following Stereotactic Body Radiation Therapy for Prostate Cancer: A Multi-institutional Analysis of Prospective Trials
    Yuan, Y.
    Fuller, D. B.
    Mardirossian, G.
    Steinberg, M. L.
    King, C. R.
    Kishan, A. U.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E278 - E278
  • [2] Health-Related Quality of Life After Stereotactic Body Radiation Therapy for Localized Prostate Cancer: Results From a Multi-institutional Consortium of Prospective Trials
    King, Christopher R.
    Collins, Sean
    Fuller, Donald
    Wang, Pin-Chieh
    Kupelian, Patrick
    Steinberg, Michael
    Katz, Alan
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (05): : 939 - 945
  • [3] Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy
    Jiang, Naomi Y.
    Dang, Audrey T.
    Yuan, Ye
    Chu, Fang-I
    Shabsovich, David
    King, Christopher R.
    Collins, Sean P.
    Aghdam, Nima
    Suy, Simeng
    Mantz, Constantine A.
    Miszczyk, Leszek
    Napieralska, Aleksandra
    Namysl-Kaletka, Agnieszka
    Bagshaw, Hilary
    Prionas, Nicolas
    Buyyounouski, Mark K.
    Jackson, William C.
    Spratt, Daniel E.
    Nickols, Nicholas G.
    Steinberg, Michael L.
    Kupelian, Patrick A.
    Kishan, Amar U.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (03): : 628 - 636
  • [4] Patterns and Predictors of Distant Failure After Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Retrospective Multi-Institutional Analysis
    Shabsovich, D.
    Xiang, M.
    Katz, A. W.
    Mantz, C. A.
    Fuller, D. B.
    van Dams, R.
    Philipson, R.
    Juarez, J. E.
    Ma, T. M.
    Pepin, A.
    Suy, S.
    Stephans, K. L.
    Murthy, V.
    Nickols, N. G.
    Miszczyk, L.
    Aghdam, N.
    Glicksman, R.
    Collins, S. P.
    Loblaw, D. A.
    Kishan, A. U.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E292 - E293
  • [5] Comparative Quality of Life Outcomes Among Brachytherapy, Intensity Modulated Radiation Therapy (IMRT), and Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer-Analysis of a Multi-Institutional Prospective Cohort
    Broughman, J. R.
    Basak, R.
    Dickerson, G. A.
    Usinger, D. S.
    Spearman, K.
    Chen, R. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E528 - E528
  • [6] Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials
    King, Christopher R.
    Freeman, Debra
    Kaplan, Irving
    Fuller, Donald
    Bolzicco, Giampaolo
    Collins, Sean
    Meier, Robert
    Wang, Jason
    Kupelian, Patrick
    Steinberg, Michael
    Katz, Alan
    RADIOTHERAPY AND ONCOLOGY, 2013, 109 (02) : 217 - 221
  • [7] Multi-institutional Analysis of Prostate-Specific Antigen Kinetics Following Stereotactic Body Radiation Therapy
    Jiang, N.
    King, C. R.
    Dang, A. T.
    Yuan, Y.
    Collins, S. P.
    Suy, S.
    Mantz, C. A.
    Miszczyk, L.
    Napieralska, A.
    Namysl-Kaletka, A.
    Nickols, N. G.
    Shabsovich, D.
    Steinberg, M. L.
    Kupelian, P. A.
    Kishan, A. U.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S106 - S107
  • [8] A Multi-institutional Phase 2 Trial Assessing Quality of Life (QOL) After Electromagnetic Transponder Guided Prostate Stereotactic Body Radiation Therapy (SBRT)
    Jackson, W. C.
    Litzenberg, D. W.
    Schipper, M.
    Wei, J.
    Rosenthal, S. A.
    Chang, G. C.
    Horwitz, E. M.
    Li, J.
    Michalski, J. M.
    Gay, H. A.
    Feng, F. Y.
    Sandler, H. M.
    Wallace, R. E.
    Hamstra, D. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E205 - E206
  • [9] Dose-Escalated Stereotactic Body radiation Therapy for Prostate Cancer: Quality-of-life Comparison of Two Prospective Trials
    Quon, Harvey C.
    Musunuru, Hima Bindu
    Cheung, Patrick
    Pang, Geordi
    Mamedov, Alexandre
    D'Alimonte, Laura
    Deabreu, Andrea
    Zhang, Liying
    Loblaw, Andrew
    FRONTIERS IN ONCOLOGY, 2016, 6
  • [10] Stereotactic Body Radiation Therapy for Unbiopsied Early-stage Lung Cancer A Multi-Institutional Analysis
    Harkenrider, Matthew M.
    Bertke, Matthew H.
    Dunlap, Neal E.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (04): : 337 - 342